Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Octreotide (Sandostatin)8 residuesFCYWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Sandostatin, Sandostatin LAR Depot, Mycapssa (oral)
Thirty-five years of clinical use and more than 12,500 published studies. Octreotide (brand name Sandostatin) is a synthetic octapeptide analog of somatostatin with three FDA-approved indications: acromegaly, carcinoid syndrome, and VIPomas. The PROMID trial (85 patients)[1] confirmed its antiproliferative activity, more than doubling time to tumor progression in metastatic midgut neuroendocrine tumors. Subcutaneous bioavailability sits near 100%. The catch: gallstones develop in 25 to 65% of long-term users, and blood glucose swings in both directions because the drug suppresses insulin and glucagon simultaneously. Endocrinologists, gastroenterologists, and oncologists prescribe it when hormonal excess or tumor growth needs controlled suppression.
Median time to tumor progression: 14.3 months versus 6.0 months on placebo. That single finding from the PROMID trial (85 patients with metastatic midgut NETs)[1] changed how oncologists manage well-differentiated neuroendocrine tumors worldwide. Octreotide (Sandostatin, CAS 83150-76-9) is a cyclic octapeptide analog of somatostatin. It binds somatostatin receptor subtypes SST2 (with subnanomolar affinity) and SST5, suppressing growth hormone, insulin, glucagon, and multiple gastrointestinal hormones. Natural somatostatin survives about 1 to 3 minutes in circulation. Octreotide stretches that to roughly 1.7 to 1.9 hours, making therapeutic dosing practical. Three FDA indications exist. In acromegaly, it lowers growth hormone and IGF-1 levels when surgery or radiation falls short, with IGF-1 normalization in roughly 50 to 70% of patients. In carcinoid syndrome, it controls the diarrhea and flushing episodes driven by metastatic carcinoid tumors. In VIPomas, it manages the profuse watery diarrhea triggered by vasoactive intestinal peptide secretion. Two formulations cover different clinical scenarios. Sandostatin Injection goes subcutaneously 2 to 3 times daily during titration. Sandostatin LAR Depot uses microsphere technology for monthly intramuscular delivery at 10 to 30 mg per injection. A generic LAR from Viatris received FDA approval in December 2025, and the oral formulation Mycapssa is available as maintenance for confirmed injectable responders. The safety profile is well-mapped. Gallstone formation (25 to 65% on long-term therapy)[2] is the headline risk. Blood glucose dysregulation, bradycardia in about 25% of patients, and GI side effects round out the clinical picture. It is a prescription medication used under direct medical supervision.
Somatostatin is the body's built-in hormonal brake. It works across the pituitary, pancreas, and gut, but its natural half-life is under three minutes. Octreotide copies the receptor-binding core of that molecule and locks it into an eight-amino-acid ring that lasts about 100 minutes instead of two. The primary target is the somatostatin receptor subtype 2 (SST2), a G protein-coupled receptor. Binding activates inhibitory G proteins (Gi/Go), which suppress adenylyl cyclase. Intracellular cAMP drops. In pituitary somatotroph cells, that shuts down growth hormone release. In pancreatic islet cells, both insulin and glucagon output fall. Across the GI tract, secretion of VIP, gastrin, secretin, and motilin all decrease. At the molecular level, octreotide binding rearranges a hydrophobic lock between transmembrane helices TM3 and TM6. That structural shift allows Galphai protein engagement. GRK2/3 kinases then phosphorylate threonine residues in the receptor's C-terminal TTETQRT motif, recruiting beta-arrestin and triggering receptor internalization. SST5 gets moderate-affinity binding, adding a second layer of hormonal suppression through intracellular calcium reduction. Beyond hormone control, SST2 activation carries separate antiproliferative actions. It upregulates the cell cycle inhibitor p27, downregulates cyclin D1, and can trigger apoptosis in somatotroph tumor cells. The PROMID trial confirmed these antiproliferative effects translate clinically: octreotide LAR significantly slowed tumor growth in well-differentiated midgut NETs (HR 0.34)[1].
Strong evidence for three FDA-approved indications: acromegaly, carcinoid syndrome (diarrhea/flushing), and VIPomas. PROMID trial demonstrated significant time-to-tumor-progression benefit in metastatic midgut NETs. 35+ years of clinical use with well-characterized PK and safety data.
PROMID: Octreotide LAR 30 mg significantly prolonged time to tumor progression vs. placebo in metastatic midgut NETs (median TTP 14.3 vs. 6.0 months; HR 0.34; PMID 19704057). ACROINNOVA 1: CAM2029 SC depot maintained normal IGF-1 in 72.2% vs. 37.5% placebo at 24 weeks (PMID 39378125).
IGF-1 normalization in only 50–70% of acromegaly patients on standard doses; gallstone formation in 25–65% on long-term therapy; glucose dysregulation complicates diabetes management; perioperative carcinoid crisis data now shows octreotide is ineffective as first-line hemodynamic rescue (PMID 38227166).
Used as prescribed for diagnosed medical conditions. r/neuroendocrine and r/acromegaly patients report octreotide as effective for symptom control but commonly cite GI side effects, injection burden (LAR IM), and gallstone formation as quality-of-life concerns. Oral Mycapssa mentioned as preferred alternative where insurance allows.
Community use matches FDA-labeled indications exactly. No significant off-label or community-only use patterns identified. The research peptide community does not use octreotide: cost, injection burden, gallstone risk, and insulin dysregulation make it impractical vs. alternatives.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | 3x Daily |
| Moderate | 100mcg | 3x Daily |
| Aggressive | 200mcg | 3x Daily |
Octreotide SC comes as a pre-filled solution. No reconstitution with bacteriostatic water needed, which makes this easier than most injectable peptides. The common vial concentrations are 50, 100, 200, and 500 mcg/mL. Check the label every single time before drawing your dose. The difference between a 50 mcg/mL vial and a 500 mcg/mL vial is a tenfold dosing error waiting to happen. For the 100 mcg/mL vial: drawing 0.5 mL gives you 50 mcg; 1.0 mL gives you 100 mcg. On a U-100 insulin syringe, 50 units equals 50 mcg from a 100 mcg/mL vial. Allow the solution to reach room temperature before injecting. Cold solution stings noticeably more. Rotate between abdomen and thigh injection sites. The thing most beginners miss: GI side effects are worst when you inject on an empty stomach. Timing your SC doses with meals or just before eating reduces diarrhea and cramping significantly. Patients who don't learn this trick early tend to have a rougher first month than necessary. Store opened vials refrigerated at 2 to 8 degrees Celsius. Stable at room temperature for up to 14 days if kept away from light.
Octreotide is typically used as continuous long-term therapy, not cycled. For acromegaly, it's maintained indefinitely while monitoring GH/IGF-1 levels. Patients on short-acting SC injections are usually transitioned to Sandostatin LAR Depot (monthly IM) once stable dosing is established. Periodic gallbladder ultrasound is recommended (every 6-12 months) due to the high incidence of gallstone formation.
Octreotide is not cycled: it is used as continuous, indefinite therapy for its FDA-approved indications (acromegaly, carcinoid syndrome, VIPomas). Discontinuation leads to return of symptoms and GH/IGF-1 rebound within days (short-acting) to weeks (LAR). No therapeutic rationale for off-periods exists in the clinical literature.
Or use the universal Peptide Calculator for any peptide.
Expected: GH suppression within days; IGF-1 reduction measurable by week 2–4. GI side effects common but typically improve.
Monitor: GH and IGF-1 at 2–4 weeks; blood glucose at initiation and after dose changes; watch for bradycardia
Octreotide SC is available at 50, 100, 200, and 500 mcg per mL. Your prescribed dose dictates which concentration you need.
Remove the vial from the refrigerator and allow it to reach room temperature (approximately 15 to 20 minutes). Cold injections cause more discomfort at the site.
It should be clear and colorless. Do not use if you see particles or discoloration.
For a 50 mcg dose from a 100 mcg/mL vial, draw 0.5 mL (50 units on a U-100 insulin syringe). For 100 mcg from the same vial, draw 1.0 mL (100 units). For 200 mcg, use either two 100 mcg/mL vials or draw 0.4 mL from a 500 mcg/mL vial (40 units on a U-100 syringe).
Clean the area with an alcohol swab.
Using a 29 to 31 gauge insulin syringe, insert the needle at a 45 to 90 degree angle into the subcutaneous tissue. Inject slowly.
Avoid injecting into the same spot twice consecutively.
For the standard acromegaly starting protocol, administer 50 mcg three times daily (every 8 hours), timed around meals. Titrate upward to 100 to 200 mcg three times daily based on GH and IGF-1 response.
Discard 14 days after first use.
Note on LAR Depot: Sandostatin LAR (10 to 30 mg monthly) is a deep intramuscular injection administered by a healthcare provider only. Never attempt to inject LAR subcutaneously or intravenously.
IV bolus: 25–50 mcg slow push; continuous infusion: 25–50 mcg/hour. Must be diluted in 50–200 mL normal saline and infused over 15–30 minutes for bolus dosing.
Not for outpatient use. Note: 2024 NCCN guideline update removed octreotide as first-line for intraoperative carcinoid crisis: vasopressors + IV fluids are now primary hemodynamic treatment (PMID 38227166). Octreotide IV remains available as adjunct.
10–30 mg q28 days IM. Relative bioavailability ~60% vs. SC immediate-release. Slower onset (2–4 weeks to steady state) with sustained therapeutic levels throughout 28-day interval.
Generic LAR (Viatris) approved Dec 18, 2025: first U.S. generic LAR formulation at significantly lower cost (est. $3,000–$5,500/dose vs. brand ~$6,760 for 30 mg). Never inject IV or SC: deep intraglutal IM only.
20–40 mg twice daily with meals. Bioavailability is highly variable and lower than SC; requires demonstrated prior injectable response. Not interchangeable with injectable dosing.
FEPBLUE prior authorization requires documented injectable response as of July 2025. Some patients prefer for quality of life (injection-free); insurance coverage is a significant barrier.
Once-monthly SC autoinjector (FluidCrystal technology). ACROINNOVA 1 showed ~5–6× higher bioavailability than octreotide LAR IM; room-temperature storage; self-administration.
NDA accepted Jan 9, 2026. If approved, would be the first self-administered monthly SC octreotide formulation in the U.S.: significant convenience advantage over provider-administered LAR IM.
Combined with octreotide in acromegaly patients with inadequate GH/IGF-1 control on SSA monotherapy. Additive GH suppression via D2 receptor pathway. Used at cabergoline doses of 0.5–3.5 mg/week.
Add cabergoline after 6 months of optimal octreotide dosing if IGF-1 still elevated
Second-line combination for acromegaly refractory to SSA alone. Pegvisomant blocks GH action peripherally; octreotide reduces GH secretion centrally. Combination allows lower pegvisomant doses.
Specialist-directed; requires close IGF-1 and LFT monitoring
Combined with octreotide LAR in progressive, well-differentiated advanced pancreatic NETs (RADIANT-3 trial support). Octreotide provides antisecretory and antiproliferative baseline; everolimus adds targeted antitumor activity.
Everolimus 10 mg/day PO + octreotide LAR 30 mg IM q28d; specialist-directed oncology protocol
Alternative SSA, not combined with octreotide but used as a direct therapeutic swap. Some patients switched from octreotide LAR to lanreotide Depot (or vice versa) for tolerability, self-injection preference (lanreotide deep SC vs. IM for LAR), or insurance coverage.
FDA-mandated interaction: octreotide must be discontinued at least 24 hours before each Lutathera dose. Somatostatin analogs compete with Lu-177 dotatate for SST2 receptor binding, reducing PRRT efficacy. Failure to hold octreotide is a patient safety issue in NET treatment.
Do not combineOctreotide significantly reduces cyclosporine intestinal absorption and blood levels, risking transplant rejection in patients on immunosuppression. Requires close cyclosporine therapeutic drug monitoring if combination is unavoidable.
Do not combineOctreotide prolongs QT interval and slows heart rate. Combined use with other QT-prolonging agents (haloperidol, amiodarone, sotalol, methadone) increases risk of torsades de pointes. ECG monitoring required.
Do not combineAdditive bradycardia risk. Octreotide independently reduces heart rate; combining with negative chronotropes can cause clinically significant bradycardia. Monitor heart rate.
Pricing updated 2026-04-09
Gallstones. That is the side effect that defines long-term octreotide use. Between 25 and 65% of acromegaly patients on maintenance therapy develop cholelithiasis [2]. Octreotide suppresses gallbladder contractility and bile secretion; stones form over months to years. Several r/acromegaly users report cholecystectomy after one to two years on the drug. Baseline gallbladder ultrasound before starting, followed by repeat imaging every 6 to 12 months, is standard practice. Some specialists prescribe prophylactic ursodiol, though this approach lacks strong trial backing. Gastrointestinal side effects are the most common acute problem. Diarrhea, nausea, abdominal pain, and flatulence affect 34 to 61% of patients (FDA Prescribing Information, 2022). Steatorrhea and cramping hit hardest in the first 1 to 3 months. The community on r/neuroendocrine describes the first week as the worst stretch, with some patients reporting they needed to stay near a bathroom. Most patients adapt by month 2 to 3, particularly when SC doses are timed with meals. Blood glucose dysregulation requires careful monitoring. Octreotide suppresses both insulin and glucagon, so glucose can swing in either direction. Hyperglycemia occurs in about 16% of patients; hypoglycemia is less common but more dangerous. Patients with diabetes need antidiabetic dose adjustments at octreotide initiation and after every dose change. Fasting glucose and HbA1c monitoring are standard at each visit during titration. Bradycardia shows up in roughly 25% of patients. Cardiac conduction abnormalities, including QT prolongation, make ECG monitoring important for anyone with a cardiac history or taking other QT-prolonging medications. Combining octreotide with beta-blockers or non-dihydropyridine calcium channel blockers adds to the heart rate reduction risk. Injection site pain affects about 7.7% of SC users. For LAR depot injections, the intramuscular delivery is consistently described as painful on r/acromegaly, though bringing the solution to room temperature for 30 minutes before injection and alternating gluteal sides each month helps. Hypothyroidism has been reported with prolonged use because octreotide inhibits TSH secretion. Annual thyroid function monitoring is part of the long-term management protocol. Vitamin B12 deficiency can emerge after extended therapy through reduced intrinsic factor and gastric acid secretion; annual B12 levels are worth checking after the first year. Less common effects include hair loss and steatorrhea that persists if the dose isn't optimized. When to seek medical attention: any sign of acute cholecystitis (sudden right upper quadrant pain, fever, nausea), symptomatic bradycardia (dizziness, fainting), or severe hypoglycemia (confusion, sweating, tremor). Discontinue if anaphylaxis occurs. Pregnancy data is limited; use only when clearly needed.
Verify Octreotide (Sandostatin) dosing and safety with a second opinion
FDA-approved prescription drug manufactured by Novartis (brand Sandostatin) and Viatris (generic LAR, approved Dec 2025). Dispensed by licensed pharmacies with documented lot-release testing. No gray-market or research-peptide vendor presence identified. Compounding access is legally restricted since octreotide is commercially available.
| Test | When | Target |
|---|---|---|
| Serum GH (growth hormone) | Every 2–4 weeks during SC titration; every 3–6 months on stable LAR | <1 ng/mL (OGTT nadir) for acromegaly control |
| Serum IGF-1 | Every 2–4 weeks during titration; every 3–6 months on stable LAR | Within age- and sex-adjusted normal range |
| Gallbladder ultrasound | Baseline before initiation; every 6–12 months on long-term therapy | — |
| Fasting blood glucose / HbA1c | At initiation, after each dose change, then every 3–6 months | — |
| TSH (thyroid function) | Baseline; every 6–12 months on long-term therapy | — |
| Liver function tests (AST, ALT, bilirubin) | Baseline; annually or with symptoms | — |
| Vitamin B12 | Annually for patients on long-term octreotide (>1 year) | — |
| ECG | At initiation in patients with cardiac history or on QT-prolonging drugs; as clinically indicated | — |
| Urinary 5-HIAA / plasma chromogranin A | Every 3–6 months for NET/carcinoid patients | — |
Primary efficacy endpoint for acromegaly. Target: GH nadir <1 ng/mL on oral glucose tolerance test.
Best surrogate for integrated GH action. Normalization for age/sex is the primary treatment goal in acromegaly.
Gallstone formation occurs in 25–65% of long-term users. SSAs reduce gallbladder contractility. Early detection allows management before acute cholecystitis.
Octreotide suppresses both insulin and glucagon: can cause hypo- or hyperglycemia. Diabetic patients require antidiabetic medication adjustment.
Octreotide inhibits TSH secretion. Hypothyroidism has been reported in patients on long-term SSA therapy.
Hepatic cirrhosis extends half-life to 3.7 hours requiring dose reduction. Biliary dysfunction and gallstone-related cholestasis can elevate LFTs during therapy.
Long-term SSA use associated with B12 malabsorption via reduction of intrinsic factor and gastric acid secretion. Not well-studied but emerging case reports.
Octreotide prolongs QT interval and reduces heart rate. Risk assessment for patients with pre-existing bradycardia, long QT, or on concomitant QT-prolonging medications.
Tumor activity biomarkers. 5-HIAA monitors serotonin production (carcinoid syndrome activity); CgA tracks overall NET tumor burden.
Peak plasma levels within 25-30 minutes of SC injection. GH suppression begins rapidly. Patients with carcinoid syndrome may notice reduced flushing and diarrhea within hours.
GH levels typically decrease within the first week of treatment. Carcinoid symptoms (diarrhea, flushing) show measurable improvement. GI side effects (nausea, loose stools, abdominal cramping) are most common during this initial period.
Dose titration based on GH/IGF-1 levels for acromegaly or symptom control for carcinoid. GI side effects tend to diminish. If transitioning to LAR, begin monthly IM injections while continuing SC for 2 weeks.
Steady-state hormone suppression achieved. IGF-1 normalization seen in approximately 50-70% of acromegaly patients. Gallbladder sludge may begin forming: baseline ultrasound recommended.
Long-term maintenance with periodic dose adjustment. Gallstone formation occurs in 25-65% of patients on prolonged therapy. Regular monitoring of glucose, thyroid function, and gallbladder status is standard practice.
First dose (0 to 6 hours): Plasma levels peak within 25 to 30 minutes of a subcutaneous injection. GH suppression kicks in within the first two hours. Carcinoid patients often notice reduced flushing frequency the same day. The most common first-dose complaints are nausea, abdominal cramping, and loose stool. Days 1 to 7: GH levels drop measurably within the first week. Carcinoid flushing episodes become noticeably less frequent. GI disruption peaks during this window; community reports on r/neuroendocrine describe the first week as rough, with diarrhea, steatorrhea, and flatulence at their worst. Rare bradycardia can show up at initiation. Weeks 2 to 4: Dose titration happens here, guided by GH and IGF-1 levels for acromegaly or symptom response for carcinoid and VIPoma patients. GI side effects start settling down for most people. Acromegaly patients report reduced sweating, softer tissue swelling, and fewer headaches by week 3 to 4. If transitioning to LAR, the first monthly injection overlaps with two more weeks of SC dosing. Months 1 to 3: Transition to LAR for patients stable on SC. Steady-state hormonal suppression builds by the third LAR injection. IGF-1 normalization occurs in roughly 50 to 70% of acromegaly patients at this point. Gallbladder sludge may begin forming; baseline ultrasound should already be done. r/acromegaly users describe the switch from daily SC to monthly LAR as a quality-of-life turning point, though the IM injection itself is briefly painful. Months 6 to 12 and beyond: Long-term maintenance with periodic dose adjustment. Gallstone formation is the defining long-term risk, hitting 25 to 65% of patients on prolonged therapy. Regular monitoring of glucose, thyroid function, gallbladder status, and vitamin B12 becomes standard. Patients on r/acromegaly report adapting to the regimen; gallstone diagnoses tend to emerge after 1 to 2 years. NET patients sometimes note fatigue related to ongoing disease management rather than the drug itself.
Peak SC plasma levels at 0.4–0.7 hours; GH suppression begins within 1–2 hours. Carcinoid flushing/diarrhea may begin to improve within hours.
Carcinoid patients report noticing reduced flushing frequency same day. Acromegaly patients describe a calming of headache and sweating within the first dose.
GH levels measurably reduced within first week. Carcinoid symptom frequency and severity improve. GI side effects (diarrhea, steatorrhea, flatulence) most pronounced in this window.
Significant GI disruption commonly reported in first week: some describe needing to stay near bathroom. Carcinoid flushing episodes notably reduced in frequency.
Dose adjustment based on GH/IGF-1 response for acromegaly; symptom control assessment for carcinoid/VIPoma. GI side effects begin improving in most patients.
GI symptoms noticeably better after the first month for most. Acromegaly patients report reduced sweating, softer tissue swelling, improved headache.
Transition to LAR if stable on SC. Steady-state hormonal suppression achievable by 3rd LAR injection. IGF-1 normalization seen in ~50–70% of acromegaly patients. Gallbladder sludge may begin forming.
Most patients report significant quality-of-life improvement vs. daily SC injections once on LAR. Some describe monthly IM injection as briefly painful but manageable.
Long-term GH/IGF-1 control with periodic dose adjustment. Gallstone formation in 25–65% on prolonged therapy. Regular monitoring of glucose, thyroid, gallbladder, and vitamin B12 (long-term SSA use associated with B12 malabsorption).
Patients report adapting to the regimen. Gallstone diagnoses emerge: several r/acromegaly users report cholecystectomy after 1–2 years. Some NET patients report fatigue from ongoing disease management rather than the drug itself.
Source: FDA prescribing information; Kutz K et al. Clin Pharmacokinet. 1992;22(1):22-31. PMID: 8287633
Loading the interactive decay curve.
Octreotide is FDA-approved under three indications: acromegaly (1988), carcinoid syndrome, and VIPomas. It requires a prescription and is classified as a prescription-only medication, not a controlled substance. Brand Sandostatin Injection and Sandostatin LAR Depot are manufactured by Novartis. A generic LAR formulation from Viatris received FDA approval on December 18, 2025, the first generic long-acting octreotide in the United States. Mycapssa (oral octreotide capsules, 20 to 40 mg twice daily) is approved for maintenance in patients who respond to injectable SSA therapy. Insurance prior authorization is common. Octreotide is not available from research peptide vendors or 503B compounding pharmacies, as it is commercially manufactured in FDA-approved forms. This restricts compounding access under federal law. Athletes should note that somatostatin and its analogs appear on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). CAM2029 (Oclaiz), a self-administered monthly SC depot, received EU approval as Oczyesa in June 2025. Its U.S. NDA has a PDUFA target date of June 10, 2026. This content is for informational purposes only and does not constitute medical advice. Octreotide should only be used under direct supervision of a qualified healthcare provider.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
